ICU Medical Inc (ICUI)
210.54
-2.10 (-0.99%)
USD |
NASDAQ |
Jan 21, 16:00
210.82
+0.28 (+0.13%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 4.472B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -3.27% |
| Valuation | |
| PE Ratio | 41.77 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 3.525 |
| Price to Book Value | 2.812 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 50.97% |
News
Headline
Wire
Time (ET)
Yahoo
01/19 09:38
Yahoo
01/18 17:38
PR Newswire
01/06 16:30
Globe Newswire
12/29 08:30
Yahoo
12/13 07:43
Yahoo
12/09 19:38
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 02/25/2022* | -- | Results | Q4 2021 | -- | 1.64 | -- | |
| 02/25/2022* | 16:30 EST | Earnings Call | Q4 2021 | -- | -- | -- | |
| 11/03/2021 | -- | Results | Q3 2021 | 2.07 | 1.80 | 15.21% | |
| 11/03/2021 | 16:30 EST | Earnings Call | Q3 2021 | -- | -- | -- | |
| 08/04/2021 | -- | Results | Q2 2021 | 1.88 | 1.64 | 14.63% | |
| 08/04/2021 | 16:30 EST | Earnings Call | Q2 2021 | -- | -- | -- | |
| 05/06/2021 | -- | Results | Q1 2021 | 1.62 | 1.54 | 5.19% | |
| 05/06/2021 | 16:30 EST | Earnings Call | Q1 2021 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| ICU Medical is a California-based, pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. After ICU’s acquisition of Hospira Infusion Systems from Pfizer in 2017, it became one of the largest players in this concentrated industry, holding top-tier positions in its major reporting segments: infusion consumables (37% of 2020 revenue), IV solutions (31%), infusion systems (28%), and critical care (4%). The combined entity remains primarily U.S. focused, generating over 70% of its sales domestically. |
| URL | http://www.icumed.com |
| Investor Relations URL | N/A |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Feb. 25, 2022 |
| Last Earnings Release | Nov. 03, 2021 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Edit comparables
Annual Total Returns Versus Peers
Edit comparables
As of January 21, 2022.
Fundamentals
| Revenue (TTM) | 1.296B |
| Total Expenses (TTM) | 1.153B |
| Net Income (TTM) | 109.35M |
| Total Assets (Quarterly) | 1.839B |
| Total Liabilities (Quarterly) | 249.38M |
| Shareholders Equity (Quarterly) | 1.590B |
| Cash from Operations (TTM) | 263.44M |
| Cash from Investing (TTM) | -98.65M |
| Cash from Financing (TTM) | 2.835M |
Ratings
Profile
Edit
| ICU Medical is a California-based, pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. After ICU’s acquisition of Hospira Infusion Systems from Pfizer in 2017, it became one of the largest players in this concentrated industry, holding top-tier positions in its major reporting segments: infusion consumables (37% of 2020 revenue), IV solutions (31%), infusion systems (28%), and critical care (4%). The combined entity remains primarily U.S. focused, generating over 70% of its sales domestically. |
| URL | http://www.icumed.com |
| Investor Relations URL | N/A |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Feb. 25, 2022 |
| Last Earnings Release | Nov. 03, 2021 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| Stocktwits | ICUI Tweets |